Onfekafusp alfa

Generic Name: Onfekafusp alfa

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: 1957239-88-1

Unique Ingredient Identifier: 6HXC0O6JMV

Background: Onfekafusp alfa is under investigation in clinical trial NCT02938299 (Neoadjuvant L19IL2/L19TNF- Pivotal Study).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Safety and Efficacy of Different Administration Sequences of L19TNF With Lomustine in Glioblastoma at First Progression

Phase 1

Withdrawn

Conditions: Glioblastoma

Interventions: Drug: Onfekafusp alfa
Drug: Lomustine

First Posted Date: 2022-03-31

Last Posted Date: 2024-04-08

Lead Sponsor: Philogen S.p.A.

Registration Number: NCT05304663

Efficacy and Safety of L19TNF in Previously Treated Patients With Advanced Stage or Metastatic Soft-tissue Sarcoma

Phase 2

Recruiting

Conditions: Soft Tissue Sarcoma

Interventions: Drug: Dacarbazine
Drug: onfekafusp alfa

First Posted Date: 2021-02-01

Last Posted Date: 2024-04-08

Lead Sponsor: Philogen S.p.A.

Target Recruit Count: 98

Registration Number: NCT04733183

Locations: 🇫🇷
Institut Bergonié, Bordeaux, France
🇵🇱
Maria Sklodowska Curie National Research Institute of Oncology, Warsaw, Poland
🇫🇷
Institut Gustave Roussy, Villejuif, France

and more 20 locations

A Study Comparing the Efficacy of L19TNF+Doxorubicin vs Doxorubicin Alone as First-line Therapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma

Phase 3

Recruiting

Conditions: Soft Tissue Sarcoma

Interventions: Drug: Doxorubicin
Drug: Onfekafusp alfa

First Posted Date: 2020-12-03

Last Posted Date: 2024-04-08

Lead Sponsor: Philogen S.p.A.

Target Recruit Count: 102

Registration Number: NCT04650984

Locations: 🇪🇸
Hospital General Universitario Gregorio Marañón, Madrid, Spain
🇪🇸
Fundación Jiménez Díaz, Madrid, Spain
🇪🇸
Hospital Universitario Virgen de las Nieves, Granada, Spain

and more 25 locations

Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma

Phase 1

Recruiting

Conditions: Glioblastoma

Interventions: Drug: Onfekafusp alfa
Drug: Temozolomide

First Posted Date: 2020-06-23

Last Posted Date: 2023-10-10

Lead Sponsor: Philogen S.p.A.

Target Recruit Count: 226

Registration Number: NCT04443010

Locations: 🇨🇭
UniversitatSpital USZ, Zürich, Switzerland

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy